SOURCE: Brower Piven, A Professional Corporation

September 25, 2009 16:20 ET

Brower Piven Encourages Investors Who Have Losses in Excess of $150,000 From Investment in Immucor, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the October 26, 2009 Lead Plaintiff Deadline

BALTIMORE, MD--(Marketwire - September 25, 2009) - Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania on behalf of purchasers of the common stock of Immucor, Inc. ("Immucor" or the "Company") (NASDAQ: BLUD) during the period between October 19, 2005 and April 23, 2009, inclusive (the "Class Period").

No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than October 26, 2009 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the Company during the Class Period. You are not required to have sold your shares to seek damages or to serve as a Lead Plaintiff. You may contact Brower Piven (through hoffman@browerpiven.com or 410/986-0036) to answer any questions you may have in that regard.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the Company's failure to disclose during the Class Period that the Company had engaged in unlawful business practices in the blood reagents industry by agreeing with its competitors to fix, raise, maintain and stabilize prices for blood reagents and related medical equipment in the U.S. market such that the Company's financial statements were false and misleading and that the Company's statements about its financial well-being and future business prospects were lacking in any reasonable basis when made. According to the complaint, on April 24, 2009, after the Company announced that it had received a grand jury subpoena from the United States Department of Justice, Antitrust Division requesting documents from September 1, 2000 through the present regarding an investigation into potential violations of the federal criminal antitrust laws in the blood reagents industry, the value of Immucor's stock declined significantly.

If you have suffered a net loss for all transactions in Immucor, Inc. common stock during the Class Period, you may obtain additional information about this lawsuit and your ability to become a lead plaintiff by contacting Brower Piven at www.browerpiven.com, by email at hoffman@browerpiven.com, by calling 410-986-0036, or at Brower Piven, A Professional Corporation, The World Trade Center-Baltimore, 401 East Pratt Street, Suite 2525, Baltimore, Maryland 21202. Attorneys at Brower Piven have combined experience litigating securities and class action cases of over 40 years. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

Contact Information

  • CONTACT:
    Charles J. Piven
    Brower Piven, A Professional Corporation
    Baltimore, Maryland
    410/986-0036
    Email Contact